Irritable Bowel Syndrome
Conditions
Brief summary
This study evaluates the effectiveness of a group cognitive behaviour therapy for Irritable Bowel Syndrome (IBS) in decreasing symptoms of IBS, improving quality of life, and normalizing the gut microbiome. Patients will complete an 11-week group cognitive behaviour therapy for IBS within 1 month of being deemed eligible for the study.
Detailed description
Irritable bowel syndrome (IBS) is a chronic, disabling functional gastrointestinal disorder that is characterized by abdominal pain or discomfort and a disturbance in bowel habit. Approximately five million Canadians currently suffer with this chronic illness, which can have a significant impact on work and school absenteeism, productivity, social functioning and quality of life (Fedorak et al., 2012). Although the etiology of IBS is still unclear, there is increased interest in the role of the gut-brain axis in the development and maintenance of IBS. A growing body of evidence has identified changes in the composition, temporal stability and metabolic activity of the gut microbiome in IBS (Bolino & Bercik, 2010). Moreover, there is evidence for bidirectional communication between the gut and the brain, such that the gut microbiota appear to influence as well as be modulated by brain activity through neurohumoral mechanisms (Collins, Surette, & Bercik, 2012). Currently, medications are the most widely used treatment for IBS (Ford et al., 2009; Ford et al., 2014). Although there is good evidence for the effectiveness of medications in reducing IBS symptomatology and improving quality of life, these medications are also often associated with unpleasant side effects. As a result, there is a growing interest in the utilization of psychological treatments, including cognitive behaviour therapy, for IBS. Cognitive behaviour therapy is a psychotherapeutic approach that addresses maladaptive cognitive processes and behaviours in a systematic, explicit fashion. Although there is good evidence for the effectiveness of cognitive behaviour therapy for the treatment of IBS (Ford et al., 2009; Ford et al., 2014), there is a lack of research examining the mechanisms through which cognitive behaviour therapy influences symptoms of IBS. Accordingly, the current study has three aims: 1) to evaluate the effectiveness of group cognitive behaviour therapy for IBS on IBS symptomatology and quality of life; 2) to examine whether there are any changes in the gut microbiome from pre to posttreatment; and 3) to examine whether changes in the gut microbiome following cognitive behaviour therapy mediate changes in IBS symptomatology and quality of life. The current study has the potential of increasing knowledge about the role of the gut microbiome in IBS as well as the mechanisms of cognitive behaviour therapy for IBS.
Interventions
BEHAVIORALGroup Cognitive Behaviour Therapy
This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
Sponsors
St. Joseph's Healthcare Hamilton
Hamilton Health Sciences Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with irritable bowel syndrome * Able to commit to attending weekly 2-hour group sessions for 12 weeks
Exclusion criteria
* Use of antibiotics, or probiotics during the 4-week period prior to enrolling in the study * Changes in medications during the 4-week period prior to enrolling in the study * Presence of a major medical illness that may change the gut microbiome (e.g., any comorbid gastroenterological, rheumatological, or immunological disorder) * Diagnosis of a major psychiatric disorder that is likely to impede participation in group therapy (e.g., depression with active suicidality, psychosis, or gross cognitive impairment) * Received psychotherapy for IBS within the past 5 years * Inability to read or complete symptom diaries or questionnaires * Inability or unwillingness to provide or sign informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Birmingham IBS Symptom Scale | baseline to 11 weeks |
| IBS Quality of Life | Baseline to 11 weeks |
| Changes in gut microbiome as assessed through analyzing fecal samples | Baseline to 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Penn State Worry Questionnaire | Baseline to 6 weeks |
| UCLA Symptom Severity Scale | Weekly for 11 weeks |
| Irritable Bowel Syndrome Symptom Severity Scale | Weekly for 11 weeks |
| GI-Cognitions Questionnaire | Baseline to 6 weeks |
| IBS Quality of Life | 11 weeks to 15 weeks |
| Birmingham IBS Severity Scale | 11 weeks to 15 weeks |
| Anxiety Sensitivity Index | Baseline to 6 weeks |
| Visceral Sensitivity Index | Baseline to 6 weeks |
| Hospital Anxiety and Depression Scale | Baseline to 6 weeks |
Countries
Canada
Outcome results
None listed